Table 1 Baseline characteristics of the study population according to the type of plaques
Variables | NP (n = 79) | CP (n = 120) | NCP/MP (n = 130) | P |
|---|---|---|---|---|
Age (years) | 50.1 ± 9.1 | 61.4 ± 9.4 | 58.2 ± 9.7 | < 0.001 |
BMI (kg/m2) | 25.1 ± 3.3 | 25.6 ± 3.6 | 25.8 ± 3.9 | 0.331 |
Male, n (%) | 39 (49.4%) | 74 (61.7%) | 92 (70.8%) | 0.008 |
Hypertension, n (%) | 28 (35.4%) | 81 (67.5%) | 84 (64.6%) | < 0.001 |
Diabetes, n (%) | 12 (15.2%) | 29 (24.2%) | 41 (31.5%) | 0.029 |
Dyslipidemia, n (%) | 39 (49.4%) | 94 (78.3%) | 114 (87.7%) | < 0.001 |
Smoking, n (%) | 16 (20.3%) | 31 (25.8%) | 43 (33.1%) | 0.117 |
Alcohol consumption, n (%) | 24 (30.4%) | 38 (31.7%) | 42 (32.3%) | 0.959 |
History of CAD, n (%) | 12 (15.2%) | 15 (12.5%) | 17 (13.1%) | 0.855 |
Biochemical parameters | ||||
 TC (mmol/L) | 4.95 ± 0.91 | 4.61 ± 1.46 | 4.57 ± 1.29 | 0.092 |
 TG (mmol/L) | 1.50 (1.18, 2.19) | 1.53 (1.03, 2.17) | 1.57 (1.17, 2.25) | 0.581 |
 HDL-C (mmol/L) | 1.20 ± 0.36 | 1.21 ± 0.33 | 1.10 ± 0.28 | 0.019 |
 LDL-C (mmol/L) | 3.07 ± 0.77 | 2.69 ± 0.88 | 2.78 ± 1.00 | 0.012 |
 hsCRP (mg/L) | 1.20 (0.65, 2.10) | 1.31 (0.64, 2.80) | 1.64 (0.81, 2.96) | 0.070 |
 FIB (g/L) | 3.09 ± 0.69 | 3.06 ± 0.53 | 3.31 ± 0.79 | 0.010 |
Medications, n (%) | ||||
 Statins | 30 (38.0%) | 83 (69.2%) | 100 (76.9%) | < 0.001 |
 Aspirin | 37 (46.8%) | 95 (79.2%) | 107 (82.3%) | < 0.001 |
 Calcium antagonists | 13 (16.5%) | 56 (46.7%) | 39 (30.0%) | < 0.001 |
 ARB/ACEI | 17 (21.5%) | 49 (40.8%) | 61 (46.9%) | 0.001 |
 Beta-blockers | 24 (30.4%) | 62 (51.7%) | 70 (53.8%) | 0.002 |
 Diuretics | 6 (7.6%) | 28 (23.3%) | 28 (21.5%) | 0.013 |